Aldeyra Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.11.24	Aldeyra Therapeutics Says FDA Accepts NDA For Reproxalap In Dry Eye Disease (RTTNews)
03.10.24	Aldeyra Therapeutics Reports Resubmission Of NDA For Topical Ocular Reproxalap (RTTNews)
11.08.24	Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray (RTTNews)
08.08.24	Aldeyra Phase 3 Study Of Reproxalap In Dry Eye Disease Meets Primary Goal; Stock Up In Pre-market (RTTNews)
28.10.23	Biotech Stocks Facing FDA Decision In November 2023 (RTTNews)
24.09.23	ALDX FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX (PR Newswire)
16.09.23	ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX (PR Newswire)
09.09.23	ROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX (PR Newswire)
02.09.23	ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALDX (PR Newswire)
26.08.23	ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX (PR Newswire)
19.08.23	ROSEN, A LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALDX (PR Newswire)
12.08.23	ROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALDX (PR Newswire)
04.08.23	ALDX INVESTOR NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action... (PR Newswire)
27.06.23	Aldeyra Reports Positive Top-line Results From Phase 2 Study Of ADX-629 In Chronic Cough (RTTNews)
21.06.23	Aldeyra Therapeutics Gets CRL From FDA For NDA Of ADX-2191 To Treat Primary Vitreoretinal Lymphoma (RTTNews)
15.06.23	Aldeyra Reports Positive Results From INVIGORATE-2 Trial Of Reproxalap In Allergic Conjunctivitis (RTTNews)
15.06.23	Pre-market Movers: EDTX, MVIS, LEJU, SPRB, LAES… (RTTNews)
11.04.23	These 7 Stocks Touched New Highs Yesterday - Did You Ride The Momentum? (RTTNews)
02.04.23	Why Aldeyra Is A Must-Watch Stock: Exciting Catalysts On The Horizon (RTTNews)
28.02.23	Aldeyra Announces Positive Results From 12-Month Trial Of Reproxalap In Dry Eye Disease (RTTNews)
21.12.22	Aldeyra Therapeutics Submits NDA For ADX-2191 (RTTNews)
12.07.22	Aldeyra Therapeutics Achieves Goals In Crossover Clinical Trial Of 0.25% Reproxalap Solution (RTTNews)
08.06.22	Aldeyra Therapeutics Reports Positive Results Of TRANQUILITY-2 Trial Of Reproxalap (RTTNews)
11.01.22	Aldeyra Reports Lower Itching, Discomfort For Reproxalap Vs Xiidra In Dry Eye Patients (RTTNews)
21.12.21	Pre-market Movers: ARDS, RELI, ALDX, QNRX, AQST… (RTTNews)
20.07.21	Aldeyra Gets FDA Orphan Drug Designation For ADX-2191 To Treat Primary Vitreoretinal Lymphoma (RTTNews)
27.04.21	Aldeyra Reports Positive Top-line Results From Phase 3 INVIGORATE Trial - Quick Facts (RTTNews)
08.01.21	ALDX Catches Eye, RVNC Faces Busy Year Ahead, SRPT Plunges On DMD Trial Data (RTTNews)
07.01.21	Stock Alert: Aldeyra Therapeutics Rising On Positive Top-line Results From Reproxalap (RTTNews)
15.07.20	AZN, IQV Team Up To Accelerate COVID-19 Vaccine Work, RIGL's ITP Drug Repurposed, IMV On Watch (RTTNews)
10.07.20	Botox, Keytruda Get FDA Approval For New Uses, BVXV Abuzz, First Droopy Eyelid Treatment Is Here (RTTNews)
24.05.20	The Week That Was: COVID-19 Drug/Vaccine Development Landscape (RTTNews)
20.05.20	ADCT Closes IPO, ALDX To Provide COVID-19 Update, RWLK To Focus On Telehealth (RTTNews)
14.04.20	Stock Alert: Aldeyra Therapeutics Inc. (ALDX) (RTTNews)
03.12.19	AGTC Awaits Data In Jan., EVFM Walks The Talk, Today's A Big Day For ALDX (RTTNews)
25.06.19	Aldeyra Therapeutics To Discontinue Noninfectious Anterior Uveitis Program (RTTNews)
11.03.19	Biotech Stocks In Focus: ALDX, AXSM, DERM... (RTTNews)
27.09.18	ALDX Catches Eyes, VLRX Eyeing China, OASM Up More Than 400% YTD (RTTNews)
20.06.18	Aldeyra Therapeutics Announces 2018 Research Day (PR Newswire)
15.05.18	Aldeyra Therapeutics Announces First Quarter 2018 Financial Results (PR Newswire)
10.05.18	Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy (PR Newswire)
09.05.18	Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results (PR Newswire)
01.05.18	Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting (PR Newswire)
24.04.18	Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial (PR Newswire)
29.03.18	Aldeyra Therapeutics Announces Year End 2017 Financial Results (PR Newswire)
22.03.18	Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results (PR Newswire)
28.02.18	TTOO Gains Steam, LPCN Up On Upgrade, ALDX Abuzz (RTTNews)
27.02.18	Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases (PR Newswire)
21.02.18	Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (PR Newswire)
30.01.18	Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Novartis	95.58	1.90 %	K V
Logitech Intl	91.48	1.35 %	K V
Part Grp Hldg	1’393.00	1.20 %	K V
Roche Hldg G	286.00	0.28 %	K V
Sonova Hldg	319.20	0.16 %	K V
Swiss Re	139.40	-0.50 %	K V
Zurich Insur Gr	553.80	-0.54 %	K V
Kuehne+Nagel Int	207.60	-0.76 %	K V
Lonza Grp	582.00	-1.49 %	K V
Nestle	77.48	-1.53 %	K V

Nachrichten zu Aldeyra Therapeutics

Aktien Top/Flop

Meistgelesene Nachrichten